Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: A 24-week follow-up study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 5, 2011, Pages 1284-1290

  Kotan, Vahap Ozan ^a   Sarandol, Emre ^b   Kirhan, Emine ^b   Ozkaya, Guven ^b   Kirli, Selcuk ^b  

^a Seydisehir State Hospital   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Major depressive disorder; Malondialdehyde; Oxidative stress

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MILNACIPRAN; MOCLOBEMIDE; PAROXETINE; RETINOL; SERTRALINE; SUPEROXIDE DISMUTASE; TIANEPTINE; TRIACYLGLYCEROL; VENLAFAXINE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MALE; OXIDATION; OXIDATIVE STRESS; PROTEIN EXPRESSION;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS; ARYLDIALKYLPHOSPHATASE; BLOOD CELL COUNT; BODY MASS INDEX; CARBOXYLIC ESTER HYDROLASES; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HORMONES; HUMANS; LIPIDS; LIVER FUNCTION TESTS; LONG-TERM CARE; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 79957815233     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.03.021     Document Type: Article

References (51)

1. Akdemir A., Orsel I., Dag H., Turkcapar H., Iscan N., Ozbay H. Validity-reliability and clinical use of Turkish version of Hamilton depression rating scale. Psikiyatri Psikol Psikofarmakol Derg 1996, 4(3P):251-259.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. Fourth Edition.
3. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64:43-51.
4. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 1978, 52:302-310.
5. Delimaris I., Georgopoulos S., Kroupis C., Zachari A., Liberi M., Bastounis E., et al. Serum oxidizability, total antioxidant status and albumin serum levels in patients with aneurysmal or arterial occlusive disease. Clin Biochem 2008, 41:706-711.
6. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
7. Eren I., Naziroglu M., Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 2007, 32(7):1188-1195.
8. Eren I., Naziroglu M., Demirdas A., Celik O., Uguz A.C., Altunbasak A., et al. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 2007, 32(3):497-505.
9. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992, 13:341-390.
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-508.
11. Galecki P., Szemraj J., Zboralski K., Florkowski A., Lewinski A. Relation between functional polymorphism of the catalase gene (-262C>T) and recurrent depressive disorder. Act Nerv Super Rediviva 2009, 51(1-2):150-155.
12. Galecki P., Szemraj J., Bienkiewicz M., Florkowski A., Galecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009, 61:436-447.
13. Galecki P., Szemraj J., Bienkiewicz M., Zboralski K., Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009, 24(4):277-286.
14. Godtfredsen N.S., Prescott E., Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005, 294(12):1505-1510.
15. Haagen L., Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992, 30:391-395.
16. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: Impact of antidepressant treatment. Arch Med Res 2007, 38:247-252.
17. Holvoet P. Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease. Ther Apher 1999, 3(4):287-293.
18. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 2004, 59(5):479-484.
19. Jong M.C., Hendriks W.L., Van Vark L.C., Dahlmans V.E., Groener J.E., Havekas L.M. Oxidized VLDL induces less triglyceride accumulation in J774 macrophages than native VLDL due to an impaired extracellular lipolysis. Arterioscler Thromb Vasc Biol 2000, 20:144-151.
20. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8(6):365-370.
21. Lett H.S., Blumenthal J.A., Babyak M.A., Sherwood A., Strauman T., Robins C., et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004, 66:305-315.
22. Lucca G., Comim C.M., Valvassori S.S., Réus G.Z., Vuolo F., Petronilho F., et al. Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochem Int 2009, 54:358-362.
23. Lucca G., Comim C.M., Valvassori S.S., Réus G.Z., Vuolo F., Petronilho F., et al. Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm. J Psychiatr Res 2009, 43(9):864-869.
24. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107:2775-2779.
25. Maes M., De Vos N., Pioli R., Demedts P., Wauters A., Neels H., et al. Lower serum vitamin E concentrations in major depression; Another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000, 58:241-246.
26. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2010, 10.1016/j.pnpbp.2010.05.004.
27. Mantovani G., Madeddu C., Macciò A., Gramignano G., Lusso M.R., Massa E., et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004, 13(10):1651-1659.
28. Matsuura E., Hughes G.R.V., Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008, 7:558-566.
29. McCormick D.B., Greene H.L. Vitamins. Tietz Textbook of Clinical Chemistry 1994, 1313-1314. W.B. Saunders, Philadelphia. C.A. Burtis, E.R. Ashwood (Eds.).
30. Michel T.M., Frangou S., Thiemeyer D., Camara S., Jecel J., Nara K., et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a postmortem study. Psychiatry Res 2007, 151:145-150.
31. Mohamed R.H., Mohamed R.H., Karam R.A., Abd El-Aziz T.A. The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 2010, 43(6):553-558.
32. Mosca L., Rubenfire M., Tarshis T., Tsai A., Pearson T. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 1997, 80:825-830.
33. Owen A.J., Batterham M.J., Probst Y.C., Grenyer B.F.S., Tapsell L.C. Low plasma vitamin E levels in major depression: diet or disease?. Eur J Clin Nutr 2005, 59:304-306.
34. Sapian-Raczkowska B., Rabczyński M., Adamiec R. Paraoxonase-important enzyme of the lipid metabolism and potential ally in the antiatherosclerotic treatment. Pol Merkur Lekarski 2010, 29(173):325-327.
35. Sarandol A., Sarandol E., Eker S.S., Karaagac E.U., Hizli B.Z., Dirican M., et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1103-1108.
36. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stres: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22:67-73.
37. Selek S., Savas H.A., Gergerlioglu H.S., Bulbul F., Uz E., Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2008, 107:89-94.
38. Serdar Z., Aslan K., Dirican M., Sarandol E., Yesilbursa D., Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006, 39:794-803.
39. Song C., Killeen A.A., Leonard B.E. Catalase, superoxide dismutase and glutathione peroxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology 1994, 30(1):24-28.
40. Teissier E., Walters-Laporte E., Duhem C., Luc G., Fruchart J.C., Duriez P. Rapid quantification of α-tocopherol in plasma and low- and high-density lipoproteins. Clin Chem 1996, 42(3):430-435.
41. Tsimikas S., Witztum J.L. The role of oxidized phospholipids in mediating lipoprotein (a) atherogenicity. Curr Opin Lipidol 2008, 19:369-377.
42. Tsuboi H., Tatsumi A., Yamamoto K., Kobayashi F., Shimoi K., Kinae N. Possible connections among job stres, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 2006, 91:63-70.
43. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
44. Wang Y., Fu W., Xie F., Wang Y., Chu X., Wang H., et al. Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population. J Hum Genet 2010, 55(8):490-494.
45. Whitman S.C., Sawyez C.G., Miller D.B., Wolfe B.M., Huff M.W. Oxidized type IV hypertriglyceridemic VLDL-Remnants cause greater macrophage cholesterol accumulation than oxidized LDL. J Lipid Res 1998, 39:1008-1020.
46. Yazici M.K., Demir B., Tanriverdi N., Karaagaoglu E., Yolac P. Hamilton Anxiety Rating Scale, Interrater reliability and validity study. Turk J Psychiatry 1998, 9:114-117.
47. Young I.S., Trimble E.R. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991, 28:504-508.
48. Zafir A., Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 2007, 572(1):23-31.
49. Zafir A., Ara A., Banu N. In vivo antioxidant status: A putative target for antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:220-228.
50. Zhang A., Vertommen J., Van Gaal L., De Leeuw A rapid and simple method for measuring the susceptibility of low-density-lipoprotein and very-low-density-lipoprotein to copper-catalyzed oxidation. Clin Chim Acta 1993, 227:159-173.
51. Zhang D., Wen X.S., Wang X.Y., Shi M., Zhao Y. Antidepressant effect of Shudihuang on mice exposed to unpredictable chronic mild stress. J Ethnopharmacol 2009, 123(1):55-60.